BSc MD - AVTE Old Senior Development
| AVTEDelisted Stock | USD 93.80 0.70 0.75% |
Executive
BSc MD is Senior Development of AVTE Old
| Phone | 617 443 2400 |
| Web | https://www.aerovatetx.com |
AVTE Old Management Efficiency
The company has return on total asset (ROA) of (0.3618) % which means that it has lost $0.3618 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5901) %, meaning that it created substantial loss on money invested by shareholders. AVTE Old's management efficiency ratios could be used to measure how well AVTE Old manages its routine affairs as well as how well it operates its assets and liabilities.AVTE Old currently holds 417 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. AVTE Old has a current ratio of 40.03, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about AVTE Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Tadimeti Rao | Design Therapeutics | N/A | |
| Edward Carr | Dianthus Therapeutics | 56 | |
| Jonathan Quick | Jade Biosciences, | N/A | |
| Benjamin Stone | AnaptysBio | N/A | |
| Jeffrey Stavenhagen | Dianthus Therapeutics | N/A | |
| Philippe Busque | Cytek Biosciences | 54 | |
| Alan Fuhrman | Tyra Biosciences | 67 | |
| Adam Esq | Dianthus Therapeutics | 39 | |
| Priya Raina | AnaptysBio | N/A | |
| John Duzer | Acrivon Therapeutics, Common | N/A | |
| Sarah Honig | Tyra Biosciences | N/A | |
| Melik Ulusu | Cytek Biosciences | N/A | |
| Eric Loumeau | AnaptysBio | 62 | |
| Amy Sullivan | Jade Biosciences, | N/A | |
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| Alan CPA | Tyra Biosciences | 68 | |
| Dr MBA | Acrivon Therapeutics, Common | 59 | |
| Jose CPA | Mineralys Therapeutics, Common | 35 | |
| Jim Kerr | Design Therapeutics | N/A | |
| MD FACC | Design Therapeutics | 56 | |
| Mustapha Parekh | Design Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.59 | |||
| Return On Asset | -0.36 |
AVTE Old Leadership Team
Elected by the shareholders, the AVTE Old's board of directors comprises two types of representatives: AVTE Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AVTE. The board's role is to monitor AVTE Old's management team and ensure that shareholders' interests are well served. AVTE Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AVTE Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Pigot, VP Commercial | ||
| Sanjeev Khindri, Executive Development | ||
| Benjamin Dake, President, Founder | ||
| Timothy MBA, CEO Director | ||
| Marinus Verwijs, Chief Officer | ||
| Stephen Yu, Senior Quality | ||
| BSc MD, Senior Development | ||
| Hunter MD, Chief Officer | ||
| MBA MR, Chief Officer | ||
| Susan Fischer, Executive Operations | ||
| Donna Dea, Head Affairs | ||
| George Eldridge, CFO Treasurer |
AVTE Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AVTE Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.59 | |||
| Return On Asset | -0.36 | |||
| Current Valuation | (526.15 K) | |||
| Shares Outstanding | 28.98 M | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 99.99 % | |||
| Number Of Shares Shorted | 4.59 M | |||
| Price To Earning | 0.64 X | |||
| Price To Book | 1.02 X | |||
| EBITDA | (74.31 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in AVTE Stock
If you are still planning to invest in AVTE Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AVTE Old's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |